France allows elderly to get AstraZeneca COVID vaccine

Ross Houston
March 3, 2021

Britain has been rolling out the AstraZeneca vaccine since January, beginning with the elderly and health workers, after approving its use for all adults.

They said that once the Ford government receives direction from the federal government on the timing of second doses and secures "final details on the recently-approved AstraZeneca vaccines", an update on the vaccine rollout will be provided.

AstraZeneca COVID-19 vaccine not recommended for seniors 65 and older: NACI

But last month, two Canadian doctors submitted a letter to the New England Journal of Medicine, which used USA data to suggest that the Pfizer-BioNTech vaccine could be 92 per cent effective against COVID-19 two weeks following the first dose.

Oxford-AstraZeneca reported about 62 per cent effectiveness at preventing COVID-19, while Pifzer-BioNTech and Moderna have said the efficacy of their vaccines is about 95 per cent.


An AstraZeneca spokesman in Seoul said the company had no comment at present.

But the news comes as turmoil reigns over who should get the AstraZeneca treatment, which was recently green-lit by the country's top health advisors. The island has yet to announce a mass vaccination campaign for the general public.


Last Friday, Canadian health regulators authorised the AstraZeneca coronavirus vaccine along with the Serum Institute of India version of the vaccine.

U.K. Health Secretary Matt Hancock unveiled what he said were "very strong" findings at a press conference in London today, where he claimed a "vaccine gap" between older people who had been immunized, and younger patients yet to receive a vaccine, was emerging.


The chance of needing hospital treatment for COVID-19 falls by more than 80 percent after a single dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech Covid jab, according to new analysis in England. However, she did urge people to take the shot when they are feeling in good health.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER